{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 77 of 81', '13.', 'Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA.', 'Effects of vasodilation in heart failure with preserved or reduced ejection fraction', 'implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol.', '2012 Jan 31;59(5):442-51.', '14.', 'Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG.', 'Mechanisms responsible for the heterogeneous coronary microvascular response to', 'nitroglycerin. Circ Res. 1991 Mar;68(3):847-55.', '15.', 'Bassenge E, Zanzinger J. Nitrates in different vascular beds, nitrate tolerance, and', 'interactions with endothelial function. Am J Cardiol. 1992 Sep 24;70(8):23b-9b', '16.', 'Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, et al. Soluble', 'guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013', 'Mar; (18(2):123-34.', '17.', 'Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C,', 'et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension', 'associated with diastolic heart failure (DILATE-1): a randomized, double-blind,', 'placebo-controlled, single-dose study. Chest. 2014 Nov;146(5):1274-85.', '18.', 'Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of', 'phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure', 'with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar', '27;309(12):1268-77', '19.', 'Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, et', 'al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart', 'failure patients with preserved ejection fraction and pulmonary hypertension: a', 'randomized controlled trial. Eur Heart J. 2015 Oct 07;36(38):2565-73', '20.', 'Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, et al.', 'Vericiguat in patients with worsening chronic heart failure and preserved ejection', 'fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE', 'patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017', 'Apr 14;38(15):1119-27', '21.', 'Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al.', 'Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J', 'Med. 2015 Dec 10;373(24):2314-24.', '22.', 'Filippatos G, Maggioni AP, Lam CSP, Pieske-Kraigher E, Butler J, Spertus J, et al.', 'Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT', 'failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED)', 'study. Eur J Heart Fail. 2017 Jun;19(6):782-91.', '23.', 'Chang C-L, Song X, Willson T, Duffy C. Abstract 220: Early Assessment of Real-', 'world Utilization and Dosing of Sacubitril/Valsartan in the US. Circulation:', 'Cardiovascular Quality and Outcomes. 2017;10(Suppl 3) A220-A.', '24.', 'Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the', 'Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart', 'failure. J Am Coll Cardiol. 2000 Apr;35(5) 1245-55.', '25.', 'Gwaltney CJ, Slagle AF, Martin M, Ariely R, Brede Y. Hearing the voice of the heart', 'failure patient: key experiences identified in qualitative interviews. Br J Cardiol.', '2012;19:25.', '26.', 'Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al.', 'Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide', 'Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 78 of 81', 'Fraction: The SOCRATES-REDUCED Randomized Trial. Jama. 2015 Dec', '1;314(21):2251-62.', '27.', 'FDA. Medical Device Development Tool (MDDT) qualification decision summary for', 'Kansas City Cardiomyopathy Questionnaire (KCCQ). Submission number', 'MDDT020. 2016; available online:', 'https://www.fda.gov/downloads/MedicalDevices/ScienceandResearch/MedicalDevice', 'DevelopmentToolsMDDT/UCM581761.pd', '28.', 'Forman DE, Alexander KP. Frailty: A Vital Sign for Older Adults With', 'Cardiovascular Disease. Can J Cardiol. 2016 Sep;32(9): 1082-7.', '29.', 'Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty', 'in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001', 'Mar;56(3):M146-56', '30.', 'Newman AB, Boudreau RM, Naydeck BL, Fried LF, Harris TB. A physiologic index', 'of comorbidity: relationship to mortality and disability. J Gerontol A Biol Sci Med', 'Sci. 2008 Jun;63(6):603-9.', '31.', 'White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, Cyr DD, et al.', 'Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary', 'syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal', 'strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.', 'European heart journal Acute cardiovascular care. 2016 Jun;5(3):231-42.', '32.', 'American Thoracic Society. ATS statement: guidelines for the six-minute walk test.', 'American journal of respiratory and critical care medicine. 2002 Jul 1;166(1): 111-7.', '33.', 'Maurer W, Bretz F. Multiple Testing in Group Sequential Trials Using Graphical', 'Approaches. Statistics in Biopharmaceutical Research. 2013 2013/11/01;5(4) 311-20.', '34.', 'Flynn KE, Lin L, Moe GW, Howlett JG, Fine LJ, Spertus JA, et al. Relationships', 'between changes in patient-reported health status and functional capacity in', 'outpatients with heart failure. Am Heart J. 2012 Jan; 163(1):88-94.e3', '35.', 'Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al.', 'Monitoring clinical changes in patients with heart failure: a comparison of methods.', 'Am Heart J. 2005 Oct;150(4):707-15', '36.', 'Dreyer RP, Jones PG, Kutty S, Spertus JA. Quantifying clinical change: discrepancies', \"between patients' and providers' perspectives. Qual Life Res. 2016 Sep;25(9):2213-20.\", '37.', 'Flynn KE, Lin L, Ellis SJ, Russell SD, Spertus JA, Whellan DJ, et al. Outcomes,', 'health policy, and managed care: relationships between patient-reported outcome', 'measures and clinical measures in outpatients with heart failure. Am Heart J. 2009', 'Oct;158(4 Suppl): S64-71.', '38.', 'Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, et al. Heart rate', 'reduction with ivabradine and health related quality of life in patients with chronic', 'heart failure: results from the SHIFT study. Eur Heart J. 2011 Oct;32(19):2395-404.', '39.', 'Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al.', 'The effect of intravenous ferric carboxymaltose on health-related quality of life in', 'patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF', 'study. Eur Heart J. 2013 Jan;34(1):30-8.', '40.', \"O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy\", 'and safety of exercise training in patients with chronic heart failure: HF-ACTION', 'randomized controlled trial. Jama. 2009 Apr 8;301 (14):1439-50.']\n\n###\n\n", "completion": "END"}